AI for drug discovery — accelerating the path from protein to medicine

This DeepMind blog explores what AlphaFold's protein structure predictions mean for pharmaceutical drug discovery — the practical application closest to Hassabis's stated goal of using AI to solve major health challenges. The post explains the drug discovery pipeline and where AlphaFold inserts: target identification (which protein is involved in a disease?), structure determination (what does that protein look like in 3D?), and hit-to-lead optimization (which small molecules bind to the protein and could become drugs?). AlphaFold addresses the second stage — historically the slowest and most expensive. With 200 million predicted structures freely available, researchers can identify binding pockets for any protein of interest without spending years on experimental structure determination. The post also describes the challenge that remains: predicting how a protein changes shape when bound to a drug (conformational dynamics), which AlphaFold2 cannot do but AlphaFold3 partially addresses. Hassabis estimates that structure-based drug discovery using AlphaFold could reduce the preclinical phase of drug development by years and billions of dollars — potentially enabling research into diseases that are currently economically unviable.